Cnbc
@cnbc·4.2M subscribers·16.1K videos
EpiPen Rival Will Return To Market Next Year | Power Lunch | CNBC
Posted
October 26, 2016
Views
383
Likes
2
Engagement
0.52%
October 26, 2016
383
2
0.52%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
Irina Koffler, Mizuho Securities, discusses why she has a buy rating on Mylan even as the news that the company's EpiPen will face more competition with the Auvi-Q auto-injector returning to the market.
» Subscribe to CNBC
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Connect with CNBC News Online
Get the latest news
Find CNBC News on Facebook
Follow CNBC News on Twitter
Follow CNBC News on Google+
Follow CNBC News on Instagram
EpiPen Rival Will Return To Market Next Year | Power Lunch | CNBC
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
